Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 17:10:1605.
doi: 10.3389/fimmu.2019.01605. eCollection 2019.

Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections

Cynthia Calzas  1 , Christophe Chevalier  1
Affiliations
Review

Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections

Cynthia Calzas et al. Front Immunol. .

Abstract

Despite efforts made to develop efficient preventive strategies, infections with influenza A viruses (IAV) continue to cause serious clinical and economic problems. Current licensed human vaccines are mainly inactivated whole virus particles or split-virion administered via the parenteral route. These vaccines provide incomplete protection against IAV in high-risk groups and are poorly/not effective against the constant antigenic drift/shift occurring in circulating strains. Advances in mucosal vaccinology and in the understanding of the protective anti-influenza immune mechanisms suggest that intranasal immunization is a promising strategy to fight against IAV. To date, human mucosal anti-influenza vaccines consist of live attenuated strains administered intranasally, which elicit higher local humoral and cellular immune responses than conventional parenteral vaccines. However, because of inconsistent protective efficacy and safety concerns regarding the use of live viral strains, new vaccine candidates are urgently needed. To prime and induce potent and long-lived protective immune responses, mucosal vaccine formulations need to ensure the immunoavailability and the immunostimulating capacity of the vaccine antigen(s) at the mucosal surfaces, while being minimally reactogenic/toxic. The purpose of this review is to compile innovative delivery/adjuvant systems tested for intranasal administration of inactivated influenza vaccines, including micro/nanosized particulate carriers such as lipid-based particles, virus-like particles and polymers associated or not with immunopotentiatory molecules including microorganism-derived toxins, Toll-like receptor ligands and cytokines. The capacity of these vaccines to trigger specific mucosal and systemic humoral and cellular responses against IAV and their (cross)-protective potential are considered.

Keywords: adjuvant; delivery systems; influenza A virus; intranasal immunization; mucosal vaccines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Rationales and challenges for the development of IAV mucosal vaccines.
See this image and copyright information in PMC

References

    1. Rajao DS, Perez DR. Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture. Front Microbiol. (2018) 9:123. 10.3389/fmicb.2018.00123 - DOI - PMC - PubMed
    1. Organization WH. Influenza (Seasonal) Fact Sheet. (2017). Available online at: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
    1. Pantin-Jackwood MJ, Swayne DE. Pathogenesis and pathobiology of avian influenza virus infection in birds. Rev Sci Tech. (2009) 28:113–36. 10.20506/rst.28.1.1869 - DOI - PubMed
    1. Tamura S, Ainai A, Suzuki T, Kurata T, Hasegawa H. Intranasal inactivated influenza vaccines: a reasonable approach to improve the efficacy of influenza vaccine? Jpn J Infect Dis. (2016) 69:165–79. 10.7883/yoken.JJID.2015.560 - DOI - PubMed
    1. Cerutti A, Chen K, Chorny A. Immunoglobulin responses at the mucosal interface. Annu Rev Immunol. (2011) 29:273–93. 10.1146/annurev-immunol-031210-101317 - DOI - PMC - PubMed

Publication types

MeSH terms